Danaher Corporation (DHR)vsGRAIL, LLC (GRAL)
DHR
Danaher Corporation
$178.19
+0.44%
HEALTHCARE · Cap: $128.18B
GRAL
GRAIL, LLC
$62.10
-9.87%
HEALTHCARE · Cap: $2.57B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 15771% more annual revenue ($24.78B vs $156.12M). DHR leads profitability with a 14.9% profit margin vs -253.2%. DHR earns a higher WallStSmart Score of 58/100 (C).
DHR
Buy58
out of 100
Grade: C
GRAL
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-54.3%
Fair Value
$114.84
Current Price
$178.19
$63.35 premium
Intrinsic value data unavailable for GRAL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.1B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 28.1% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
3.7% revenue growth
ROE of 7.0% — below average capital efficiency
0.0% earnings growth
ROE of -15.8% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bull Case : GRAL
The strongest argument for GRAL centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 28.1% demonstrates continued momentum.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : GRAL
The primary concerns for GRAL are EPS Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
DHR profiles as a value stock while GRAL is a growth play — different risk/reward profiles.
GRAL is growing revenue faster at 28.1% — sustainability is the question.
DHR generates stronger free cash flow (1.1B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DHR scores higher overall (58/100 vs 35/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
GRAIL, LLC
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
GRAIL, LLC is a pioneering biotechnology company at the forefront of cancer diagnostics, focusing on innovative blood tests for multi-cancer early detection (MCED) that utilize its proprietary genomic technologies. Committed to advancing precision medicine, GRAIL aims to transform the oncology landscape by providing individuals with essential insights for proactive health management and improving overall patient outcomes. Its groundbreaking efforts address significant unmet needs in cancer screening and diagnostics, positioning the company as a key player in the rapidly evolving field of cancer care.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?